FDA announces voluntary recall of Sandoz ranitidine capsules following detection of an impurity
The U.S. Food and Drug Administration is alerting health care professionals and patients of a voluntary recall of 14 lots of prescription ranitidine capsules distributed by Sandoz Inc., used to decrease the amount of acid created by the stomach. This recall is due to a nitrosamine impurity, N-nitrosodimethylamine (NDMA), which was found in the recalled medicine. NDMA is classified as a probable human carcinogen (a substance that could cause cancer). (Source: World Pharma News)
Source: World Pharma News - September 24, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Maker Halts Distribution of Generic Zantac Due to Possible Carcinogen
A distribution halt is not the same as a full recall, and it means that generic Zantac (ranitidine) remaining on store shelves can still be sold, CBS News reported. (Source: WebMD Health)
Source: WebMD Health - September 20, 2019 Category: Consumer Health News Source Type: news

Drugmaker halts shipments of ranitidine heartburn medication after contaminant found
Drugmaker Novartis said it is halting distribution of all ranitidine medicines made by Sandoz, a measure it called "precautionary" after the acid-reducing medications were found to contain an impurity. (Source: CNN.com - Health)
Source: CNN.com - Health - September 19, 2019 Category: Consumer Health News Source Type: news

Novartis Stops Distributing Generic Zantac Over Potential Cancer-Causing Ingredient
WASHINGTON (CBS) – Drug maker Novartis has halted distribution of generic versions of Zantac. The popular heartburn medication has been investigated for containing a potential cancer-causing ingredient. A Novartis spokesman told CBS News “our internal investigation is ongoing to determine further details,” and the drug can remain on pharmacy shelves for now. Sanofi, the French pharmaceutical company that makes Zantac, said it had no plans to stop distribution or production. Last week, the FDA said that ranitidine treatments like Zantac have been found to contain a “probable” carcinogenic impurity known as N-nitro...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 19, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Consumer Health News Syndicated CBSN Boston FDA Zantac Source Type: news

Novartis halts distribution of Zantac drug amid probe into impurities
Novartis AG's Sandoz unit said Wednesday it was halting distribution of its versions of the ranitidine drug known as Zantac in all its markets, including the United States and Canada, after contaminants were found in the heartburn drug. (Source: CBC | Health)
Source: CBC | Health - September 18, 2019 Category: Consumer Health News Tags: News/Health Source Type: news

Possible carcinogen found in popular heartburn meds
Regulators in the U.S. and EU are taking a closer look at medication containing ranitidine after the presence of a probable carcinogen was found in several samples. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - September 16, 2019 Category: Pharmaceuticals Source Type: news

FDA Warning About Heartburn Medications, What Is The Contaminant?
Some products containing ranitidine, such as Zantac, may have a contaminant that could cause cancer at higher levels. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 14, 2019 Category: Pharmaceuticals Authors: Bruce Y. Lee, Contributor Source Type: news

FDA finds cancer-causing chemical in heartburn medicine Zantac
Small amounts of a cancer-causing chemical have been found in the popular heartburn medication Zantac, as well is in generic forms of the drug, known as Ranitidine. The FDA is not issuing a recall and says patients can continue taking the medication. Zantac's maker says it takes patient safety seriously and is committed to working with the FDA. Dr. David Agus joins “CBS This Morning: Saturday” to discuss what consumers need to know. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - September 14, 2019 Category: Consumer Health News Source Type: news

FDA Updates and Press Announcements on NDMA in Zantac (ranitidine)
Updates and Press Announcements regarding NDMA in Zantac (ranitidine) medicines. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 14, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Zantac (ranitidine): Safety Information - NDMA Found in Samples of Some Ranitidine Medicines
FDA has learned that some ranitidine medicines, including some products commonly known as the brand-name drug Zantac, contain NDMA. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 14, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

U.S and European regulators reviewing safety of heartburn drugs like Zantac
U.S. and European drug regulators said on Friday they are reviewing the safety of the widely taken heartburn drug ranitidine, commonly known by the brand name Zantac, after they found traces of a probable cancer-causing impurity in some versions of the medicine. (Source: Reuters: Health)
Source: Reuters: Health - September 13, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Finds Low Levels Of Cancer-Linked Impurity In Common Heartburn Drugs
(CNN) — The US Food and Drug Administration said on Friday that it has learned that some ranitidine — acid-reducing and heartburn medicines, including those known by the brand name Zantac — contain low levels of an impurity that could cause cancer. The nitrosamine impurity known as N-nitrosodimethylamine or NDMA has been classified as a probable human carcinogen based on lab tests, and this isn’t the first time that it has been detected in a common medication. Since last year, the FDA has been investigating NDMA and other impurities in blood pressure and heart failure medicines known as angiotensin ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 13, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN FDA Heartburn Source Type: news

Zantac Heartburn Drug May Contain Carcinogen: FDA
While preliminary tests found low levels of the nitrosamine impurity N-nitrosodimethylamine (NDMA) in some ranitidine products, the FDA said this does not mean patients taking the drugs should stop using them now. (Source: WebMD Health)
Source: WebMD Health - September 13, 2019 Category: Consumer Health News Source Type: news

FDA: Zantac May Contain Small Amounts of Known Carcinogen
FRIDAY, Sept. 13, 2019 -- A substance that could cause cancer has been found in some ranitidine heartburn and ulcer medicines, including the brand-name drug Zantac, and the source of this contamination is being investigated, the U.S. Food and Drug... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 13, 2019 Category: Pharmaceuticals Source Type: news

FDA, EU Investigating Probable Carcinogen in Heartburn Meds FDA, EU Investigating Probable Carcinogen in Heartburn Meds
Drug regulators in the US and Europe find the probable carcinogen NDMA in heartburn medicines containing ranitidine, reminiscent of the ' sartan ' contamination saga.News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 13, 2019 Category: Cancer & Oncology Tags: Gastroenterology News Alert Source Type: news